Recent clinical data on rhythm control strategies and implications for patient care
Back to course
Video Transcription
0:00
Hi, my name is Paulus Gerjof and today I'm going to talk about recent clinical data on rhythm control strategies and implications for patient care. These are my disclosures.
0:18
Now, the starting point of the new data that I want to talk to you about was summarized in the design paper of the EAST-AFN 412 published in 2013.
0:30
And it shows you, this busy table shows you the event rates in rate versus rhythm and rhythm control and anticoagulation trials in atrial fibrillation.
0:42
And you can appreciate two things. One, even on optimal anticoagulation rate control and background therapy of compromising
0:50
conditions, there is still a measurable rate of stroke and cardiovascular death and also heart failure hospitalizations in patients with atrial fibrillation.
0:59
And two, and I've marked the Athena data in green, there is one signal that suggests that rhythm control therapy using antiarrhythmic drugs may reduce that rate.
Video Summary
In this video, Paulus Gerjof discusses recent clinical data on rhythm control strategies for atrial fibrillation (AF). He highlights that even with optimal anticoagulation and background therapy, there is still a measurable rate of stroke, cardiovascular death, and heart failure hospitalizations in AF patients. The EAST-AF 412 trial tested whether early rhythm control therapy, incorporating antiarrhythmic drugs, could reduce these outcomes. The trial found that early rhythm control therapy reduced cardiovascular events by 21% over five years. The therapy was delivered mainly through antiarrhythmic drugs. The findings suggest that early rhythm control therapy should be considered the default strategy for most AF patients, especially the elderly and those with multiple comorbidities.
Keywords
rhythm control strategies
atrial fibrillation
early rhythm control therapy
antiarrhythmic drugs
cardiovascular events
Android App Download IOS App Download Powered By